ConstipationPhase 2/3NCT02073006
A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation
A Phase 2/3 study testing Natural Fibre Supplement in people with Constipation, run by Atlantia Food Clinical Trials at 1 site in Ireland.
Trial summary
Constipation is common in the general population, especially in women and in the elderly. Hard stool is a complaint often associated with constipation, which suggests that stool softening would provide a major benefit in the strategy of treatment. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Constipation
- What is being tested?
- Natural Fibre Supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteIreland
- Study dates
- Feb 2014to Oct 2014
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- To be considered eligible for enrolment into the study, subjects must;
- Be able to give written informed consent,
- Be between 18 and 80 years of age,
- Subject has chronic functional constipation according to the Rome III Diagnostic Criteria, where (f) is mandatory.
- Must include two or more of the following:
- Straining during at least 25% of defæcations
Show all 13Show fewer
- Lumpy or hard stools in at least 25% of defæcations
- Sensation of incomplete evacuation for at least 25% of defæcations
- Sensation of anorectal obstruction / blockage for at least 25% of defaecations
- Manual manœuvers to facilitate at least 25% of defæcations (e.g., digital evacuation, support of the pelvic floor)
- Fewer than 3 defæcations per week ii. Loose stools are rarely present without the use of laxatives iii. Insufficient criteria for irritable bowel syndrome * Criteria fulfilled for the last 3 months, with symptom onset at least 6 months prior to diagnosis
- Subjects will continue on his/her normal diet,
- The subject agrees to complete the Patient Diary for two weeks prior to study entry and for the duration of the study.
Who cannot join
- Subjects will be excluded from the study if they meet any of the below criteria;
- Are less than 18 and greater than 80 years of age,
- Females are pregnant, lactating or wish to become pregnant during the study.
- Are hypersensitive to any of the components of the test product,
- Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigators judgement, entry to the study,
- Subject has an obstructive or metabolic aetiology for constipation,
Show all 14Show fewer
- Subject has a history of laxative abuse (greater than the daily dosage recommended on the label for any laxative),
- Subject has used a probiotic or prebiotic product or a dietary fibre supplement in the 4 weeks prior to the baseline visit,
- Subject has a history of drug and/or alcohol abuse at the time of enrolment
- Having a condition or have taken a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results;
- Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial,
- Subjects may not be receiving treatment involving experimental drugs,
- If the subject has been in a recent experimental trial, these must have been completed not less than 90 days prior to this study.
- Have a malignant disease or any concomitant end-stage organ disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomised, Double-blind, Placebo-Controlled, Parallel Study to Evaluate the Effects of Lepicol® in Adults With Chronic, Functional Constipation
Constipation is common in the general population, especially in women and in the elderly. Hard stool is a complaint often associated with constipation, which suggests that stool softening would provide a major benefit in the strategy of treatment.
This investigative fibre product is primarily a soluble dietary fibre with added probiotics and a prebiotic. It is not digested in the small intestine and partly remains undigested by bacteria in the gut. Also, as probiotics are believed to help restore a healthy gut flora, reduce pH, assist with digestion of food and reduce gaseous by-products they may aid the improvement of intestinal motility.
The objective of this study is to assess if this investigative, fibre product effects the number of bowel movements per week and if this in turn impacts quality of life and symptoms of constipation.
Read the detailed description
Constipation is a common condition. Perception of a healthy bowel movement varies widely within and among populations but the Rome III Criteria is a standardised tool that diagnoses functional constipation on the basis of the following symptoms for the last 3 months with symptom onset at least 6 months prior to diagnosis:
- Must include two or more of the following:
- Straining during at least 25% of defecations
- Lumpy or hard stools in at least 25% of defecations
- Sensation of incomplete evacuation for at least 25% of defecations
- Sensation of anorectal obstruction/blockage for at least 25% of defecations
- Manual manoeuvres to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
- Fewer than three defecations per week
- Loose stools are rarely present without the use of laxatives
- Insufficient criteria for irritable bowel syndrome
Additional to being extremely uncomfortable, untreated constipation can lead to faecal impaction (with resulting faecal incontinence), particularly in elderly and confused people and is believed to be a risk factor for haemorrhoids (piles) and diverticular disease. However even without a medical diagnosis the undesired symptoms can reduce perceived quality of life and successful management may involve a number of factors. Standard treatment consists of disimpaction and the administration of laxatives to achieve a normal bowel habit of passing a soft stool without pain. The daily use of laxatives long term is often advised against as it can make your body dependent on them, causing your bowel to no longer function normally.
Stool softening is a physician's first step in the management of chronic constipation. Psyllium has been shown to soften stools by increasing stool water content, far more than most common dietary fibres. It forms a soft gel which eases the stool along the lower digestive tract ready for evacuation. This bulkier faeces presses on the wall of the intestine, stimulating the muscles to contract and force the contents forward, a process known as 'peristalsis'. If there is insufficient fibre in the diet, the faeces will move more slowly and there will be more time for water to be absorbed from the ingested food into the rest of the body, leaving the faeces smaller and harder, which in turn is more difficult to move. Psyllium has the advantage of being much gentler than some common fibres (such as wheat bran) that can be irritating to a sensitive bowel.
Studies using psyllium in a range of doses of 7g up to 24g a day show positive results in relation to increasing stool frequency and weight, and improving stool consistency, in turn improving associated abdominal pain and discomfort. These results were applicable in both adults and the elderly. Although psyllium works in a much more gentle natural way, in some studies it was seen to be superior to or comparative to commonly used laxatives.
Probiotics had the added advantage of improving stool frequency and consistency and accompanying abdominal pain, most likely by their positive effects on the gut microflora often seen to be imbalanced in those with constipation. These effects were seen in infants, adults and the elderly with no adverse events such inducing loose stools.
Lastly, inulin in a range of doses of 1.5g up to 50g a day was seen to improve not only beneficial bacteria counts but also bowel transit in infants, adults and the elderly and in one study was again seen to be more effective than a common laxative but without the side effects.
This study aims to increase the body of scientific data on psyllium by way of a randomised, placebo-controlled study.
- Conditions
- Constipation
- Being tested
- Natural Fibre Supplement
- Keywords
- Chronic, Functional, Constipation, less than 3 bowel movements per week
- Medical subject headings
- Constipation, Bronchiolitis Obliterans Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Natural Fibre SupplementDietary supplement
Also called Lepicol
Natural Fibre Supplement 2 doses per day for 4 weeks
| Study group | Role | What they receive |
|---|---|---|
| Natural Fibre Supplement | Active comparator | 2 doses per day for 4 weeks Receives: Dietary Supplement: Natural Fibre Supplement |
| Placebo | Placebo comparator | 2 doses per day for 4 weeks Receives: Dietary Supplement: Natural Fibre Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of bowel movements per week
Measured: 4 weeks
Secondary outcomes (4)
Stool consistency, as measured by the Bristol Stool Form Scale
Measured: 4 weeks
Quality of life as measured by the Quality of Life Questionnaire (PAC-QOL)
Measured: 4 weeks
Constipation symptoms as measured by PAC-SYM
Measured: 4 weeks
Laxative use by subjects with functional constipation
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2014 (estimated)
- Study startFeb 2014
- Primary completionJul 2014
- Study completionOct 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ConstipationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Atlantia Food Clinical Trials
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Fergus Shanahan, MD,FRCP,FACG, Principal investigator, Cork University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02073006
- Sponsor's protocol ID
- AFCRO-048
- Status last verified
- Jan 2015
- First submitted
- 25 Feb 2014
- Last updated
- 15 Jan 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-blind, Placebo-Controlled, Parallel Study to Evaluate the Effects of Lepicol® in Adults With Chronic, Functional Constipation
- ClinicalTrials.gov ID
- NCT02073006
- Acronym / sponsor ID
- AFCRO-048
- Conditions
- Constipation
- Keywords
- Chronic, Functional, Constipation, less than 3 bowel movements per week
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Atlantia Food Clinical TrialsIndustry (pharma, biotech, devices)
- Study start
- Feb 2014
- Primary completion
- Jul 2014 (actual)
- Study completion
- Oct 2014 (actual)
- First posted
- 27 Feb 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Constipation is common in the general population, especially in women and in the elderly. Hard stool is a complaint often associated with constipation, which suggests that stool softening would provide a major benefit in the strategy of treatment.
This investigative fibre product is primarily a soluble dietary fibre with added probiotics and a prebiotic. It is not digested in the small intestine and partly remains undigested by bacteria in the gut. Also, as probiotics are believed to help restore a healthy gut flora, reduce pH, assist with digestion of food and reduce gaseous by-products they may aid the improvement of intestinal motility.
The objective of this study is to assess if this investigative, fibre product effects the number of bowel movements per week and if this in turn impacts quality of life and symptoms of constipation.
Detailed description
Constipation is a common condition. Perception of a healthy bowel movement varies widely within and among populations but the Rome III Criteria is a standardised tool that diagnoses functional constipation on the basis of the following symptoms for the last 3 months with symptom onset at least 6 months prior to diagnosis:
- Must include two or more of the following:
- Straining during at least 25% of defecations
- Lumpy or hard stools in at least 25% of defecations
- Sensation of incomplete evacuation for at least 25% of defecations
- Sensation of anorectal obstruction/blockage for at least 25% of defecations
- Manual manoeuvres to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
- Fewer than three defecations per week
- Loose stools are rarely present without the use of laxatives
- Insufficient criteria for irritable bowel syndrome
Additional to being extremely uncomfortable, untreated constipation can lead to faecal impaction (with resulting faecal incontinence), particularly in elderly and confused people and is believed to be a risk factor for haemorrhoids (piles) and diverticular disease. However even without a medical diagnosis the undesired symptoms can reduce perceived quality of life and successful management may involve a number of factors. Standard treatment consists of disimpaction and the administration of laxatives to achieve a normal bowel habit of passing a soft stool without pain. The daily use of laxatives long term is often advised against as it can make your body dependent on them, causing your bowel to no longer function normally.
Stool softening is a physician's first step in the management of chronic constipation. Psyllium has been shown to soften stools by increasing stool water content, far more than most common dietary fibres. It forms a soft gel which eases the stool along the lower digestive tract ready for evacuation. This bulkier faeces presses on the wall of the intestine, stimulating the muscles to contract and force the contents forward, a process known as 'peristalsis'. If there is insufficient fibre in the diet, the faeces will move more slowly and there will be more time for water to be absorbed from the ingested food into the rest of the body, leaving the faeces smaller and harder, which in turn is more difficult to move. Psyllium has the advantage of being much gentler than some common fibres (such as wheat bran) that can be irritating to a sensitive bowel.
Studies using psyllium in a range of doses of 7g up to 24g a day show positive results in relation to increasing stool frequency and weight, and improving stool consistency, in turn improving associated abdominal pain and discomfort. These results were applicable in both adults and the elderly. Although psyllium works in a much more gentle natural way, in some studies it was seen to be superior to or comparative to commonly used laxatives.
Probiotics had the added advantage of improving stool frequency and consistency and accompanying abdominal pain, most likely by their positive effects on the gut microflora often seen to be imbalanced in those with constipation. These effects were seen in infants, adults and the elderly with no adverse events such inducing loose stools.
Lastly, inulin in a range of doses of 1.5g up to 50g a day was seen to improve not only beneficial bacteria counts but also bowel transit in infants, adults and the elderly and in one study was again seen to be more effective than a common laxative but without the side effects.
This study aims to increase the body of scientific data on psyllium by way of a randomised, placebo-controlled study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Natural Fibre Supplement | Active comparator | Dietary Supplement: Natural Fibre Supplement2 doses per day for 4 weeks |
| Placebo | Placebo comparator | Dietary Supplement: Natural Fibre Supplement2 doses per day for 4 weeks |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- To be considered eligible for enrolment into the study, subjects must;
- Be able to give written informed consent,
- Be between 18 and 80 years of age,
- Subject has chronic functional constipation according to the Rome III Diagnostic Criteria, where (f) is mandatory.
- Subjects will continue on his/her normal diet,
Key exclusion criteria (14 listed)
- Subjects will be excluded from the study if they meet any of the below criteria;
- Are less than 18 and greater than 80 years of age,
- Females are pregnant, lactating or wish to become pregnant during the study.
- Are hypersensitive to any of the components of the test product,
- Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigators judgement, entry to the study,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Natural Fibre SupplementAlso: LepicolNatural Fibre Supplement 2 doses per day for 4 weeks | Dietary supplement | Natural Fibre Supplement, Placebo |
Primary outcome
Number of bowel movements per week
Time frame: 4 weeks
4 secondary outcomes
Stool consistency, as measured by the Bristol Stool Form Scale
Time frame: 4 weeks
Quality of life as measured by the Quality of Life Questionnaire (PAC-QOL)
Time frame: 4 weeks
Constipation symptoms as measured by PAC-SYM
Time frame: 4 weeks
Laxative use by subjects with functional constipation
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2015.
Related trials for Constipation
Recruiting
Effects of a Prebiotic-Probiotic Combination on Constipation Symptoms and Quality of Life
Constipation, Abdominal Pain
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
Recruiting
Outcome Research in Bowel Irrigation Techniques for the Treatment of Chronic Constipation and/or Faecal Incontinence
Faecal Incontinence, Chronic Constipation
Active, not recruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Functional Constipation (FC)
Not yet recruiting
Acupuncture Combined With Transcutaneous Electrical Acupoint Stimulation for Constipation-Predominant Irritable Bowel Syndrome With Anxiety State
IBS, Constipation Predominant, Anxiety State
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fergus Shanahan, MD,FRCP,FACG principal investigator
Cork University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Natural Fibre Supplement in people with Constipation, run by Atlantia Food Clinical Trials at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of bowel movements per week (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2015.